After Cyfendus' full approval, Emergent clinches $75M anthrax vaccine supply pact in US

Preview

来源: FiercePharma

Under the newly modified deal, deliveries of Cyfendus are expected to begin this year and wrap up by the end of 2024’s first quarter, Emergent said.

Armed with a full FDA approval after four years of supplying its anthrax vaccine under a pre-emergency use authorization, Emergent BioSolutions is expanding its countermeasure supply pact with the United States.

The nation’s Biomedical Advanced Research and Development Authority (BARDA) is laying out $75 million to exercise an option on an existing deal for additional doses of Emergent’s two-dose anthrax shot Cyfendus, according to a securities filing.

The FDA signed off on Emergent’s vaccine—formerly known as AV7909—in July. Prior to the shot’s formal green light, Emergent had been furnishing the U.S. Department of Health and Human Services with the product since 2019.

The immunization includes anthrax vaccine absorbed (AVA) and an adjuvant and is administered as two doses over 14 days. It’s intended for post-exposure prophylaxis in adults 18 to 65.

Under the newly modified deal, deliveries of Cyfendus are expected to begin this year and wrap up by the end of March 2024, Emergent said. The company did not specify how many doses it’s supplying to the U.S.

BARDA and Emergent first extended their partnership to develop and manufacture Cyfendus back in 2016. After submitting a pre-emergency use authorization package in December 2018, Emergent delivered the first pre-EUA doses of Cyfendus to the U.S. government in 2019.

For years, supplying medical countermeasures to the government has formed Emergent’s bread-and-butter business. Aside from its anthrax shot, Emergent produces vaccines for smallpox and Ebola, as well as the popular opioid overdose reversal agent Narcan.

Emergent’s 4mg Narcan nasal spray, for its part, won a historic over-the-counter approval back in March, teeing up direct-to-consumer sales at places like drug stores, convenience stores, supermarkets and gas stations.

Meanwhile, big changes have been brewing at Emergent this year. In late June, Emergent’s long-time CEO Robert Kramer stepped down from all his posts, lining up an interim replacement in Haywood Miller, the managing director of Berkely Research Group.

Come August, Emergent announced it was de-emphasizing its CDMO services business to shore up its work on core medical countermeasures and Narcan. In turn, the company unveiled plans to eliminate its chief operating officer and ax hundreds of jobs.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。